Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOTOXIS: SENS-401 for Prevention of Cisplatin-Induced Ototoxicity
NCT05628233Phase 2Completed
- Sponsor
- Sensorion
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arazasetron besylate in ototoxicity, sponsored by Sensorion. Started Dec 2022; status: completed.
02
Drugs
arazasetron besylate
03
Conditions
ototoxicity
Beyond the preview
Go deeper on NCT05628233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628233.